Dr. George Magrath: How Opus Breaks Trial Bottlenecks

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/4f/10/62/4f1062ef-66c3-a0fa-e529-316c138639f1/mza_6497164257034567976.jpg/600x600bb.jpg

Breaking Protocol

Tilda

5 episodes

4 days ago

The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. Tune in every week as Tilda Research CEO Ram Yalamanchili interviews clinical trial leaders at the cutting edge of innovation who are breaking past the current paradigm.

Life Sciences

Science

RSS

All content for Breaking Protocol is the property of Tilda and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43670737/43670737-1747239163791-0989f8fe827aa.jpg

Dr. George Magrath: How Opus Breaks Trial Bottlenecks

Breaking Protocol

48 minutes 4 seconds

5 months ago

Dr. George Magrath: How Opus Breaks Trial Bottlenecks

A powerful conversation with Dr. George Magrath, CEO of Opus Genetics and seasoned ophthalmologist, as he shares how AI is reshaping clinical trials, and the incredible impact of AI teammates on his clinical research program. From cutting trial timelines to boosting enrollment, George reveals real-world wins in biotech and gene therapy for rare childhood blindness. Opus' near sci-fi levels of science is restoring vision for blind adults. Learn how AI is easing site coordinator burden, accelerating research, and making once-impossible treatments a reality.